Skip to content
Disclosery

ARCH Venture Management, LLC

Follow

13F filer, CIK 1274403, CHICAGO, IL

ARCH Venture Management, LLC reported $1,100,261,770 across 12 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-14. Its ten largest share positions make up 99.27% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001012975-26-000794

Period
2026-06-30
Reported value
$1.1B
Holdings
12
Top 10 weight
99.27%
New
3
Sold out
1

Largest buys vs the previous quarter

SecurityShares changeApprox. value
PBLSnew+6,412,780$176M
SPTXnew+6,294,951$137M
BOLDnew+2,694,095$6.74M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
VIRreduced-222,500-$2.27M
QTTBexited-320,482-$2.06M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2026

Share positions as resolved from 13F-HR 0001012975-26-000794, largest first. % of portfolio is the value over $1,100,261,770, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PBLSPARABILIS MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 6,412,780 shares 6,412,780$176M15.95%newTimeline
BEAMBEAM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 4,834,653 shares; 2024Q4: 4,540,132 shares; 2025Q1: 4,540,132 shares; 2025Q2: 4,540,132 shares; 2025Q3: 4,540,132 shares; 2025Q4: 4,540,132 shares; 2026Q1: 4,540,132 shares; 2026Q2: 4,540,132 shares 4,540,132$156M14.16%0Timeline
RAPPRAPPORT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 3,728,738 shares; 2024Q4: 3,728,738 shares; 2025Q1: 3,728,738 shares; 2025Q2: 3,728,738 shares; 2025Q3: 3,728,738 shares; 2025Q4: 3,728,738 shares; 2026Q1: 3,728,738 shares; 2026Q2: 3,728,738 shares 3,728,738$155M14.12%0Timeline
SPTXSEAPORT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 6,294,951 shares 6,294,951$137M12.42%newTimeline
ERASERASCA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 11,055,554 shares; 2024Q4: 11,055,554 shares; 2025Q1: 11,055,554 shares; 2025Q2: 11,055,554 shares; 2025Q3: 11,055,554 shares; 2025Q4: 11,055,554 shares; 2026Q1: 7,091,557 shares; 2026Q2: 7,091,557 shares 7,091,557$130M11.81%0Timeline
VIRVIR BIOTECHNOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 12,916,663 shares; 2025Q3: 12,916,663 shares; 2025Q4: 12,916,663 shares; 2026Q1: 12,916,663 shares; 2026Q2: 12,694,163 shares 12,694,163$129M11.76%-222,500Timeline
MAZEMAZE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 4,120,053 shares; 2025Q2: 4,120,053 shares; 2025Q3: 4,120,053 shares; 2025Q4: 4,120,053 shares; 2026Q1: 4,120,053 shares; 2026Q2: 4,120,053 shares 4,120,053$123M11.18%0Timeline
LYELLYELL IMMUNOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,820,634 shares; 2025Q3: 2,759,072 shares; 2025Q4: 2,759,072 shares; 2026Q1: 3,247,162 shares; 2026Q2: 3,247,162 shares 3,247,162$45.5M4.14%0Timeline
GENBGENERATE BIOMEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,944,426 shares; 2026Q2: 1,944,426 shares 1,944,426$32.8M2.98%0Timeline
TXG10X GENOMICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 737,539 shares; 2026Q1: 217,834 shares; 2026Q2: 217,834 shares 217,834$8.35M0.76%0Timeline
BOLDBOUNDLESS BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 2,694,095 shares 2,694,095$6.74M0.61%newTimeline
GOSSGOSSAMER BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 8,055,916 shares; 2024Q4: 8,055,916 shares; 2025Q1: 8,055,916 shares; 2025Q2: 8,055,916 shares; 2025Q3: 8,055,916 shares; 2025Q4: 8,055,916 shares; 2026Q1: 8,055,916 shares; 2026Q2: 8,055,916 shares 8,055,916$1.33M0.12%0Timeline

Sold out in Q2 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
QTTBQ32 BIO INC320,482$2.06Mshares

How Q2 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001012975-26-000794 base2026-08-14acceptance time not in the bulk data set

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
13F-HR 0001012975-26-000794 Quarter ended 2026-06-302026-08-14acceptance time not in the bulk data set
13F-HR 0001012975-26-000461 Quarter ended 2026-03-312026-05-15acceptance time not in the bulk data set
13F-HR 0001012975-26-000153 Quarter ended 2025-12-312026-02-17acceptance time not in the bulk data set
13F-HR 0001012975-25-000787 Quarter ended 2025-09-302025-11-14acceptance time not in the bulk data set
13F-HR 0001012975-25-000444 Quarter ended 2025-06-302025-08-14acceptance time not in the bulk data set
13F-HR 0001012975-25-000245 Quarter ended 2025-03-312025-05-15acceptance time not in the bulk data set
13F-HR 0001012975-25-000089 Quarter ended 2024-12-312025-02-14acceptance time not in the bulk data set
13F-HR 0001012975-24-000476 Quarter ended 2024-09-302024-11-14acceptance time not in the bulk data set
13F-HR 0001012975-24-000339 Quarter ended 2024-06-302024-08-14acceptance time not in the bulk data set
13F-HR 0001012975-24-000230 Quarter ended 2024-03-312024-05-15acceptance time not in the bulk data set
13F-HR 0001012975-24-000083 Quarter ended 2023-12-312024-02-14acceptance time not in the bulk data set
13F-HR 0001012975-23-000461 Quarter ended 2023-09-302023-11-14acceptance time not in the bulk data set
13F-HR 0001012975-23-000327 Quarter ended 2023-06-302023-08-09acceptance time not in the bulk data set
13F-HR 0001012975-23-000217 Quarter ended 2023-03-312023-05-15acceptance time not in the bulk data set
13F-HR 0001012975-23-000091 Quarter ended 2022-12-312023-02-14acceptance time not in the bulk data set
13F-HR 0001012975-22-000487 Quarter ended 2022-09-302022-11-10acceptance time not in the bulk data set
13F-HR 0001012975-22-000354 Quarter ended 2022-06-302022-08-15acceptance time not in the bulk data set
13F-HR/A 0001012975-22-000255 Quarter ended 2022-03-312022-05-27acceptance time not in the bulk data set
13F-HR 0001012975-22-000225 Quarter ended 2022-03-312022-05-13acceptance time not in the bulk data set
13F-HR 0001012975-22-000080 Quarter ended 2021-12-312022-02-14acceptance time not in the bulk data set
13F-HR 0001012975-20-000837 Quarter ended 2020-09-302020-11-16acceptance time not in the bulk data set
13F-HR 0001012975-20-000678 Quarter ended 2020-06-302020-08-12acceptance time not in the bulk data set
13F-HR 0001012975-20-000401 Quarter ended 2020-03-312020-05-06acceptance time not in the bulk data set
13F-HR 0001512848-20-000003 Quarter ended 2019-12-312020-02-05acceptance time not in the bulk data set
13F-HR 0001012975-19-000673 Quarter ended 2019-09-302019-11-12acceptance time not in the bulk data set
13F-HR 0001012975-19-000544 Quarter ended 2019-06-302019-08-09acceptance time not in the bulk data set
13F-HR/A 0001012975-19-000385 Quarter ended 2018-12-312019-05-17acceptance time not in the bulk data set
13F-HR 0001012975-19-000343 Quarter ended 2019-03-312019-05-14acceptance time not in the bulk data set
13F-HR 0001012975-19-000162 Quarter ended 2018-12-312019-02-14acceptance time not in the bulk data set